VK2735 for Weight Management Phase 2 (Venture Oral Dosing)

What Was Tested

In this phase 2 trial, researchers set out to test VK2735.

VK2735 or matched placebo will be administered once daily.

It had seven arms (groups): Placebo Assignment (placebo comparator), one (experimental), one (experimental), one (experimental) and one (experimental).

VK2735 (Placebo) administered Daily.

VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily.

VK2735 is a peptide GLP-1 and GIP dual agonist administered Daily.

The registry classes the interventions as drug.

Who Took Part

Enrollment: 280 actual participants took part.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Age ≥18 years of age at the time of signing the informed consent. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co-morbid condition (treated or untreated), and BMI \<50 kg/m2. Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. BMI calculated at the Screening visit will be used to determine eligibility.

The full record lists 4 inclusion and 7 exclusion criteria; among the exclusions: current or past diagnosis of diabetes mellitus (including type 1, type 2, gestational); current or past diagnosis of chronic pancreatitis; calcitonin ≥50 ng/l measured by central laboratory at screening (individuals with elevated calcitonin at initial screening may be re-screened).

How the Study Was Run

Design: randomized, parallel-group and triple-blind.

The participants were allocated by chance, so the VK2735 group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

As a double-blind VK2735 study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2024-12-18 with completion listed for 2025-06-24.

It ran at 15 sites in United States (15).

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: Percent (relative) change from baseline in body weight after 13 weeks of treatment (time frame: 13 Weeks).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of VK2735 in 280 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the VK2735 compound page, all human trials.